Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies

Abstract Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post-hoc analysis of two phase III studies in patients with PsA treated with tofacitinib assessed dactylitis by location, and the impact on patient-reported outcomes (PROs). Methods...

Full description

Bibliographic Details
Main Authors: Ana-Maria Orbai, Philip J. Mease, Philip S. Helliwell, Oliver FitzGerald, Dona L. Fleishaker, Rajiv Mundayat, Pamela Young
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Rheumatology
Subjects:
Spondyloarthritis
Psoriatic arthritis
Patient-reported outcomes
Dactylitis
Tofacitinib
Online Access:https://doi.org/10.1186/s41927-022-00298-4

Internet

https://doi.org/10.1186/s41927-022-00298-4

Similar Items